Interleukin-6 in SARS-CoV2 risk stratification
F. Pereira da Silva (Guarda, Portugal), F. Luís (Guarda, Portugal), F. Jesus (Guarda, Portugal), É. Almeida (Guarda, Portugal), S. Braga (Guarda, Portugal), J. Ribeiro (Guarda, Portugal), R. Natal (Guarda, Portugal), J. Costa (Guarda, Portugal), M. Tavares (Guarda, Portugal), L. Ferreira (Guarda, Portugal)
Source: International Congress 2022 – COVID infections prognosis: risk factors and treatment
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Pereira da Silva (Guarda, Portugal), F. Luís (Guarda, Portugal), F. Jesus (Guarda, Portugal), É. Almeida (Guarda, Portugal), S. Braga (Guarda, Portugal), J. Ribeiro (Guarda, Portugal), R. Natal (Guarda, Portugal), J. Costa (Guarda, Portugal), M. Tavares (Guarda, Portugal), L. Ferreira (Guarda, Portugal). Interleukin-6 in SARS-CoV2 risk stratification. 3380
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|